PRESS-RELEASE filed Nov 2, 2026 at 16:28 ET
Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY, and adjusted diluted EPS of $0.14, beating the consensus estimate of $0.09. The company narrowed its full-year 2026 revenue guidance to $850M-$860M (from $835M-$875M) and maintained adjusted EPS guidance of $1.20-$1.40. Revenue decline was driven by coding and reimbursement headwinds, partially offset by higher-margin Inspire V mix and a new CPT code approval for 2028.